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Abstract
Background Benzimidazoles are often used concomitantly
with protease inhibitors in patients with helminthic disease
and HIV infection. Low bioavailability and extensive first-
pass metabolism make benzimidazoles prone to pharmaco-
kinetic drug interactions. The aim of the present study was
to investigate potential drug interactions between the
benzimidazoles albendazole and mebendazole and the
potent CYP3A4 inhibitor ritonavir.
Methods Sixteen healthy volunteers were administered a
single oral dose of 1,000 mg mebendazole or 400 mg
albendazole (2×n=8). AUC, Cmax, and t1/2 of mebendazole,
albendazole, and albendazole sulfoxide were studied in
absence and after short-term (2 doses) and long-term
(8 days) treatment with ritonavir 200 mg bid.
Results Pharmacokinetic parameters of albendazole and
mebendazole were not changed by short-term administra-
tion of ritonavir. However, long-term administration of
ritonavir resulted in significant changes in albendazole and
mebendazole disposition, with a significant decrease in
AUC0-24 (27 and 43% of baseline for albendazole and
mebendazole, respectively) and Cmax (26 and 41% of
baseline, respectively).
Conclusion The AUC0-24 of benzimidazoles decreased
after long-term use of ritonavir, while no changes in
pharmacokinetic profiles were observed under short-term
administration. These findings might help to optimize
benzimidazole efficacy when used in combination with
protease inhibitors.
Keywords Benzimidazoles . Albendazole . Mebendazole .
Ritonavir . Drug interaction
Introduction
Albendazole and mebendazole are benzimidazoles used for
the therapy of various helminthic infections as well as for
the treatment of hydatid disease (Echinococcus granulo-
sus) and alveolar echinococcosis (Echinococcus multi-
locularis) [1]. The combination of benzimidazoles with
anti-HIV medications such as protease inhibitors is
increasingly used in developing countries, where both
helminthic disease and HIV infection are endemic [2].
While HIV therapy is not affected by co-administration of
benzimidazoles [2], no data are so far available on the
effect of protease inhibitors on antiparasitic treatment.
However, low bioavailability and extensive first-pass
metabolism make benzimidazoles especially prone to
pharmacokinetic drug interactions, and dose-related tox-
icity could therefore arise in combination with potent
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inhibitors of benzimidazole metabolism. In line with these
concerns, a metabolic drug interaction was recently
suggested as the underlying pathophysiological mecha-
nism of a case of severe dose-related hematological
toxicity described under comedication of albendazole
and mebendazole with the protease inhibitors ritonavir
and nelfinavir [3].
After oral administration, albendazole and mebendazole
are poorly absorbed in the intestinal tract, mainly due to
limited solubility [4]. Furthermore, benzimidazoles undergo
extensive intestinal and hepatic bioconversion, adding to
the low systemic exposures with these compounds [5, 6]. In
case of albendazole, different cytochrome P450 enzymes
(CYP) and the flavine-containing monooxygenase (FMO)
system seem to be responsible for intestinal and hepatic
sulfoxidation of the parent compound to albendazole
sulfoxide [6, 7], while CYP1A2 is involved in sulfonidation
[8]. Formation of albendazole sulfoxide is stereoselective
with CYP3A4 being the key player in the formation of (-)-
albendazole sulfoxide, whereas formation of (+)-albenda-
zole sulfoxide is mediated by the FMO system [7]. In line
with these observations, co-administration of CYP3A4
inhibitors such as cyclosporine or ketoconazole was
associated with increased albendazole plasma levels in
different animal models, which was interpreted as a result
of inhibited intestinal elimination of albendazole [9].
Furthermore, the non-selective cytochrome P450 inhibitor
clotrimazole and the FMO inhibitor methimazole signifi-
cantly inhibited albendazole metabolism in rat liver micro-
somes [7]. In contrast, only few data are available on
specific enzymes involved in the metabolism of mebenda-
zole. Metabolites isolated from feces and urine as well as
results of the aminopyrine breath test suggest the involve-
ment of a keton reductase and different CYP isoforms [10,
11]. Furthermore, interaction data in healthy volunteers
indicate that the non-specific cytochrome P450 (CYP)
inhibitor cimetidine significantly increases mebendazole
plasma levels [10, 12], pointing towards an involvement of
cytochrome P450 enzymes in mebendazole metabolism.
The protease inhibitor ritonavir is among the most potent
inhibitors of the CYP3A system [13]. Consequently,
interaction of protease inhibitors with drugs that are cleared
predominantly by CYP3A enzymes are profound and
clinically significant [14]. It is still equivocal whether
long-term administration of ritonavir may also lead to a
certain induction of CYP3A enzymes [15]. However,
studies both in healthy volunteers [16] and patients [17]
do not support CYP3A4 induction.
Given the lack of systematic data on the disposition and
interaction of benzimidazoles with protease inhibitors the
aim of the present study was to investigate potential drug
interactions between the benzimidazoles albendazole and
mebendazole and ritonavir under single-dose and steady-
state conditions. The protease inhibitor ritonavir was
chosen as model inhibitor because of its anticipated use in
combination with benzimidazoles and its reported associa-
tion with dose-related toxicity of albendazole and meben-
dazole. Furthermore the effect of long-term administration
of ritonavir on benzimidazole metabolism was investigated.
Methods
Patients and study design
After approval by the local ethics committee and written
informed consent, 16 healthy, nonsmoking, HIV-negative
male Caucasian volunteers were included in the study. All
participants had to be healthy as confirmed by physical
examination and routine laboratory screening of hematolog-
ical and clinical-chemical parameters, including renal, hepatic,
and pancreatic parameters. None of the participants took any
regular medication, and all abstained from alcohol for the
duration of the study. Because of possible gender-related
differences in the pharmacokinetic profiles of albendazole
metabolites [18], only male volunteers were included.
The study was performed at the Clinical Research Unit
of the University Hospital Zürich. To minimize food-
associated variability in absorption, study medication was
administered after an overnight fast. Volunteers were
given a single oral dose of 1,000 mg mebendazole
(Vermox tablets 500 mg, Janssen-Cilag, Baar Switzerland)
(n=8 individuals) or 400 mg albendazole (Zentel tablets,
GlaxoSmithKline, Münchenbuchsee, Switzerland)
(n=8 individuals). Mebendazole and albendazole were
taken in the morning of three independent days (days 1, 8,
and 15) with 100 ml water. Oral ritonavir 200 mg bid
(Norvir 100 mg capsules, Abbott, Baar, Switzerland) was
started in the evening of day 7 and was continued until the
morning of day 15. Standardized breakfast and lunch were
served after the 2-h and the 4-h blood samples.
Pharmacokinetic profiles of albendazole and mebenda-
zole were performed on day 1 (baseline), day 8 (after 2
doses of ritonavir), and day 15 (long-term ritonavir). Blood
samples for the analysis of albendazole and mebendazole
were drawn from a venous line before and after 30 min and
1, 2, 3, 4, 6, 10, and 24 h after the benzimidazole
administration. Ritonavir samples were taken once in the
morning of day 8 and 15 for compliance control. All blood
samples were immediately centrifuged at 4°C and the
plasma stored at -20°C until further analysis.
Study participants were allowed to leave the trial unit on
the evenings of day 1, 8, and 15 and returned for the
'24-h sample on the following morning. On the last
pharmacokinetic day (day 15), a liver, pancreatic, and renal
panel was performed for safety reasons.
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Analysis of albendazole and mebendazole
Plasma concentrations of albendazole, its active metabolite
albendazole sulfoxide, mebendazole, and ritonavir were
measured at the Institute of Clinical Chemistry, University
Hospital Zurich. Albendazole, albendazole sulfoxide, and
mebendazole with flubendazole as internal standard (IS)
were determined by liquid chromatography tandem mass
spectrometry with positive atmospheric pressure chemical
ionization (LC-MS/MS). The different benzimidazoles were
separated with reversed-phase chromatography using a
gradient system of ammoniumformiate buffer pH 3,
methanol, and acetonitrile. A 1-ml sample of plasma was
extracted by solid-phase extraction using C18 columns.
Elution was performed with 2 ml methanol containing 2.5%
dimethyl sulfoxide. Quantitation was achieved using se-
lected reaction monitoring (SRM) of the transitions of m/z
266→234 for albendazole, m/z 282→240 for albendazole
sulfoxide, m/z 296→264 for mebendazole, and m/z
314→282 for the IS.
The standard curves were plotted as the peak area ratio
of the respective benzimidazole to the internal standard. To
assess linearity, the best fit was determined by least square
regression. The accuracy of the method was 103% for
albendazole, 102% for albendazole sulfoxide, and 101% for
mebendazole, respectively. The intra- and interday coef-
ficients of variation were <10% for all analytes.
Pharmacokinetic analysis
Changes in albendazole and mebendazole pharmacokinetics
were evaluated under concomitant short-term (day 8) and
long-term (day 15) intake of ritonavir. The maximum
plasma concentration (Cmax) and the time of occurrence of
Cmax (Tmax) were taken from concentration time curves.
Plasma concentrations of albendazole, albendazole sulfox-
ide, and mebendazole were plotted semi-logarithmically
against time, and the AUC was calculated by the
trapezoidal rule for the periods from 0 to 24 h. The
apparent terminal half-life (t1/2) was estimated by non-
compartmental analysis using the pharmacokinetic software
WinNonlin Version 5.0. (Pharsight, Cary, NC).
Power calculation
The aim of this study was to compare pharmacokinetic
profiles of albendazole and mebendazole under concomi-
tant short-term and long-term administration of the
CYP3A4 and P-glycoprotein inhibitor ritonavir. Changes
in AUC0-24 and Cmax were chosen as primary endpoints.
Sample size calculation was based upon the following
considerations: (1) the extent of interindividual variability
in albendazole pharmacokinetics in healthy volunteers [4],
(2) the extent of interindividual variability of multiple-dose
oral ritonavir pharmacokinetics in healthy volunteers [19],
(3) the observed increase in simvastatin AUC in an
interaction study with ritonavir [20], as simvastatin exhibits
a bioavailability comparable to that of mebendazole and
albendazole, and (4) the observed increase in mebendazole
plasma concentrations under co-treatment with ritonavir in
a single-case observation [3]. While the expected increase
in Cmax and AUC of benzimidazoles is about 20-fold under
short-term use of ritonavir, the increase is expected to level
off to about 4-fold under long-term use. Eight individuals
per group are required to detect this 4-fold increase from
baseline kinetics with a power of 80% and a significance
level of 0.05.
Data analysis
Primary parameters for the assessment of an interaction
were the AUC0-24 and the Cmax of the three analytes
(multiplicative models applied), while Tmax and t1/2 were
additionally investigated. The interaction was handled as a
bioequivalence problem [21]. The effect of short-term and
long-term administration of ritonavir on the pharmacoki-
netics of mebendazole, albendazole, and albendazole
sulfoxide was evaluated. Point estimates and the
corresponding 90% confidence intervals of the two
geometric mean ratios of the pharmacokinetic parameters
in the study periods with ritonavir over those without
ritonavir were calculated. An interaction was accepted to
be present if the 90% confidence interval around the
geometric mean ratio was entirely outside the accepted
reference range of 0.80-1.25.
Results
Study participants and safety
Sixteen healthy male volunteers were enrolled in this
study, eight in the albendazole and eight in the mebenda-
zole arm. The mean age of study participants was 31 years
(range 20–46 years) and the mean weight was 73 kg
(range 60–101 kg). All volunteers successfully completed
the study. Two of the participants complained about slight
diarrhea while taking ritonavir, which reversed without
sequelae. No serious adverse events occurred.
Albendazole and mebendazole kinetics
Individual pharmacokinetic parameters showed high in-
terindividual variability: individual albendazole and
albendazole sulfoxide AUC0-24 values differed by more
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than 20-fold and mebendazole AUC0-24 values differed
more than 7-fold on the first pharmacokinetic day
(Fig. 1a–c). Outliers with excessively high AUC0-24 and
Cmax values were seen in single individuals (individual 3
for albendazole, due to double-peaked plasma concentra-
tion time curves, and individual 9 for mebendazole; data
not shown). The pharmacokinetics of albendazole, its
metabolite albendazole sulfoxide, and mebendazole were
not significantly changed by the administration of short-
term ritonavir as the 90% confidence interval of AUC0-24
and Cmax overlapped the bioequivalence criteria (0.80-
1.25) (Table 1). Apart from individual 3 with a strong
decrease in albendazole and albendazole sulfoxide AUC
on the second PK-day after intake of two doses of
ritonavir (Fig. 1b, c), only minimal changes in individual
albendazole and albendazole sulfoxide AUC0-24 values
were seen in the remaining study participants. The trend
toward a decrease in the AUC0-24 mean value in the
albendazole group on the second PK-day is probably due
to the AUC0-24 outliers on the first PK-day. In the
mebendazole group, a trend towards an increase in
mebendazole exposure after short-term intake of ritonavir
was seen. Four of eight participants (individuals 10, 12,
15, and 16) had an increase in mebendazole exposure of
30–80%, while three individuals exhibited hardly any
change in exposure, and in one individual AUC0-24
decreased by 35%.
Administration of ritonavir for 1 week, however,
resulted in significant changes in albendazole and meben-
dazole disposition, with a significant decrease in AUC0-24
and Cmax compared to baseline values (Table 1 and
Fig. 2a–c). Mebendazole AUC0-24 and Cmax were reduced
to 0.43 and 0.41 (geometric mean ratio) of baseline values,
respectively, while albendazole and albendazole sulfoxide
AUC0-24 and Cmax were reduced to 0.27 and 0.26 and to
0.41 and 0.52, respectively. The confidence intervals of
the geometric mean ratios were outside the bioequivalence
criteria, so that an interaction had to be accepted as
present. This was also true when geometric mean ratios
were recalculated without the outliers for both groups, i.e.,
individual 3 for albendazole [GM ratios AUC0-24 :0.30
(0.14-0.60) and Cmax: 0.26 (0.09-0.70)] and individual 9
for mebendazole [GM ratios AUC0-24 :0.45 (0.29-0.69)
and Cmax: 0.45 (0.28-0.72)]. Only the GM ratios for
albendazole sulfoxide slightly overlapped the bioequiva-
lence criteria for the AUC [GM ratios AUC0-24 :0.57
(0.34-0.95) and Cmax: 0.43 (0.27-0.68)]. At the same time,
Tmax and the terminal half-life did not change significant-
ly. In all individuals, ritonavir was detected in the plasma
on the second and the third PK-day with concentrations
ranging from 0.14 to 10 mg/l. In two individuals in the
mebendazole group who complained about slight diarrhea
between the second and the third PK-day, AUC0-24
dropped by 70% on the third PK-day. A diminished
absorption of mebendazole caused by increased intestinal
activity can therefore not fully be excluded in these
particular cases.
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Fig. 1 Individual AUC0-24 on different pharmacokinetic days of a
mebendazole, b albendazole, and c albendazole sulfoxide. The
horizontal lines represent mean values
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Discussion
In the present study we investigated the effect of short- and
long-term administration of ritonavir on the disposition of
the benzimidazoles albendazole and mebendazole in
healthy volunteers. As expected from previous data on oral
albendazole and mebendazole disposition [4, 12], high
interindividual variability in bioavailability was seen. While
single-dose administration of the potent CYP3A inhibitor
ritonavir did not result in changes in albendazole and
mebendazole plasma concentrations in most of the patients,
long-term administration led to a significant decrease in
benzimidazole systemic exposure.
Inhibition of albendazole and mebendazole metabolism
under co-administration of ritonavir has been expected
based upon the low oral bioavailability of these drugs and
evidence for an important contribution of cytochrome P450
enzymes to in-vitro metabolism [22]. While the relative
contribution of different CYP enzymes has not been
identified for mebendazole, CYP3A seems to be one of
the key players for albendazole biotransformation [7].
However, albendazole has been classified as a high-
clearance drug, with hepatic metabolism being essentially
flow-limited [22].
On the other hand, significant drug interaction after oral
administration can still arise at the level of intestinal drug
absorption, where metabolizing enzymes and transporter
systems expressed in small intestinal enterocytes represent
an important first presystemic barrier. Recent evidence
points towards an involvement of the breast cancer
resistance protein BCRP (ABCG2) in this process, while
MDR1 P-glycoprotein, which could potentially be inhibited
by ritonavir, is not involved in benzimidazole transport
[23]. Overall, flow-limited hepatic metabolism and pre-
dominant intestinal clearance by BCRP would explain the
observation that albendazole disposition is not affected by
intake of two doses of ritonavir.
In contrast, ritonavir is an inducer of several phase I and
phase II enzymes and transporters [24] in a dose-dependent
manner. A 12% decrease in ritonavir exposure was already
seen with doses of 400 mg daily, and exposure further
decreased by 45% with ritonavir 1,000 mg/day [19]. An
increase in cytochrome 2C9, 2C19, and 1A2 activity by
ritonavir was shown in human hepatocytes [15] as well as
under long-term treatment with lopinavir boosted with
200 mg ritonavir daily in healthy volunteers [16]. As
CYP2C9 and CYP1A2 are involved in albendazole and
albendazole sulfoxide metabolism [22], their induction by
long-term ritonavir administration of 400 mg daily could
explain a lower bioavailability of albendazole. Accordingly,
a partial involvement of CYP2C and CYP1A2 enzymes in
mebendazole metabolism could be postulated as an even
more pronounced reduction in mebendazole was noted in our
study. Induction of phase II enzymes could represent an
Table 1 Pharmacokinetic parameters of mebendazole, albendazole, and albendazole sulfoxide before and after short-term (two doses) and long-
term (8 days) treatment with ritonavir in eight healthy volunteers
Before ritonavir Short-term ritonavir Long-term ritonavir
Mean±SDa Mean±SDa Geometric
mean (GM)
ratiob
90% Confidence
interval of GM
ratios
Mean±SDa Geometric
mean (GM)
ratiob
90% Confidence
interval of GM
ratios
Mebendazole
AUC0-24 (µg·h/l) 207.2±157.6 228.9±147 1.17 0.81–1.70 85.9±53.2 0.43 0.30–0.62
Cmax (µg/l) 31.0±26.0 36.0±22.8 1.18 0.79–1.80 11.5±6.2 0.41 0.27–0.63
Tmax (h) 2.1±1 2.4±1.7 2.1±0.8
Terminal t1/2 (h) 7.4±2.2 9.3±3.5 10.6±8.6
Albendazole
AUC0-24 (µg·h/l) 100.1±110.8 56.6±28.1 0.83 0.42–1.61 23.6±20.7 0.27 0.14–0.52
Cmax (µg/l) 15.3±10.3 16.0±9 1.24 0.52–2.95 4.9±5.2 0.26 0.11–0.62
Tmax (h) 2.1±1.1 1.8±1.1 2.3±1.8
Terminal t1/2 (h) 10.2±10.2 10.1±7.3 17.3±15.5
Albendazole sulfoxide
AUC0-24 (µg·h/l) 5,441.3±4,725.2 3,299.8±1,249.8 0.77 0.50–1.20 2,354.0±1,896.6 0.41 0.26–0.65
Cmax (µg/l) 453.9±398.7 273.3±119.6 0.79 0.50–1.26 230.9±151.4 0.52 0.32–0.83
Tmax (h) 4.1±3.6 2.9±2.0 3.6±3.1
Terminal t1/2 (h) 17.3±13.6 13.2±5.6 8.9±4.6
a Arithmetic mean
b Ratio of geometric means (GM) of values under short- or long-term ritonavir treatment to values before treatment with ritonavir
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alternative explanation as the CYP system is only partially
involved and mebendazole conjugates are excreted as metab-
olites [11]. Ritonavir induces UDP-glucuronosyltransferase
1A1 (UGT1A1) in vitro [25], and plasma concentrations of
substances mainly conjugated by UGT-like lamotrigine are
markedly reduced by ritonavir co-administration [26].
Intraindividual variability due to poor and variable
absorption of the low water-soluble drugs albendazole and
mebendazole might also have contributed to the observed
reduction in exposition. Albendazole and mebendazole
absorption is increased by fatty meals [4], and a pH
dependency has been postulated for albendazole absorption
[27]. To evaluate the importance of variability in intestinal
absorption on our findings, data were recalculated without
the outliers with the highest AUC values in the albendazole
group (individual 3) and the mebendazole group (individual
9). Even by excluding these individuals from our analysis,
decrease in AUC and Cmax for albendazole and mebenda-
zole after long-term ritonavir administration still did not
meet the bioequivalence criteria, pointing towards a
mechanism other than differences in drug absorption to be
responsible for our observations. The slight overlap with
the bioequivalence criteria of the albendazole metabolite is
unlikely to be primarily due to differences in intestinal
absorption. Furthermore, as no differences in Cmax and
AUC values were observed between individuals with and
without diarrhea, changes in gastrointestinal motility were
not considered to be the main reason for the overall
decrease in albendazole and albendazole sulfoxide AUC
under long-term ritonavir intake.
Several conclusions can be drawn from this study:
First, CYP3A and P-glycoprotein inhibition by ritonavir
does not affect albendazole or mebendazole disposition,
and there should be no concern about dose-related
benzimidazole toxicity when using combination therapies
with protease inhibitors. Furthermore, with some caution,
these observations can be extrapolated to other drugs
known to inhibit CYP3A or P-glycoprotein, which very
probably can safely be co-administered in patients with
helminthic disease. Second, as BCRP seems to be a
determinant of intestinal elimination of albendazole
metabolites, inhibition or induction of this efflux process
might potentially result in drug interactions. However, the
in-vivo significance of BCRP inhibition remains to be
determined and seems to be insignificant in the case of
ritonavir. Third, long-term use of this combination results
in decreased exposure of albendazole and mebendazole
and might therefore affect treatment efficacy. This effect
is most probably not only due to a ritonavir-mediated
induction of metabolizing enzymes or transporters but
could be related to low intestinal absorption and changes
in gastrointestinal function.
However, although our data help to mechanistically
understand the effect of ritonavir on benzimidazole
metabolism and transport, they do not reflect the clinical
treatment reality of HIV-infected patients, where ritona-
vir is almost never given as the single protease inhibitor
Fig. 2 Serum concentration time curves on different pharmacokinetic
days of a mebendazole, b albendazole, and c albendazole sulfoxide.
Baseline values (day 1) are represented by black circles, short-term
ritonavir by white circles, and long-term ritonavir by triangles. Error
bars represent standard deviation
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but instead is given as part of a combination therapy.
The effect of boosted protease inhibitor combinations
such as lopinavir/ritonavir or atazanavir/ritonavir, which
are components of standard drug regimens in HIV
patients, on mebendazole and albendazole kinetics, can
therefore not definitely be deduced from our study.
Furthermore, depending on whether benzimidazoles are
given to treat intestinal or systemic parasites, a decrease
in systemic bioavailability might even be considered an
advantage, if intestinal drug levels were increased.
However, suggestions concerning therapeutic drug mon-
itoring for the treatment of patients with HIV and
echinococcus co-infection cannot yet be given, since no
concentration ranges to avoid toxicity or optimize
efficacy have been established.
In conclusion, our data show that benzimidazoles
exposure decreases after long-term use of ritonavir, while
no significant changes in pharmacokinetic profiles are
observed under short-term administration. These results
are important for the safe and effective administration of
these substances in certain areas of the world and should be
tested for their clinical significance to optimize benzimid-
azole efficacy when used in combination with protease
inhibitors.
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